Retinoblastoma is a retinal cancerous disease that primarily affects young children. To date, preservation of the eye and its functionality is secondary to saving the child’s life. EpCAM+ Y79 retinoblastoma cells behave like cancer stem cells that are recognized as cells that are resistant to treatment. Additionally, reoccurrence of tumours is attributed to the persistence of cancer stem cells. An effective technique to treat retinoblastoma cancer cells is demonstrated using femtosecond laser pulses and EpCAM targeting gold nanorods (Au-NRs). Both fluorescence viability assay and MTS cellular metabolism assay confirm an astonishing cellular viability drop, to ~10%. It is shown that right after laser irradiation the cellular membrane ruptures. FESEM imaging shows that Au-NRs reach melting temperature after laser pulse exposure. The medium of the eye is transparent to NIR laser irradiation, making this treatment ideal for this type of cancer. This treatment methodology would also be an invaluable tool for treatment of chemotherapy-resistant and radiation-resistant cancers.
Nir Katchinskiy, Roseline Godbout, Ali Hatef, and Abdulhakem Y. Elezzabi, "Proof of concept: anti-EPCAM gold nanorods and femtosecond laser pulses for retinoblastoma treatment," Proc. SPIE 10685, Biophotonics: Photonic Solutions for Better Health Care VI, 106850I (Presented at SPIE Photonics Europe: April 24, 2018; Published: 17 May 2018); https://doi.org/10.1117/12.2306966.
Conference Presentations are recordings of oral presentations given at SPIE conferences and published as part of the proceedings. They include the speaker's narration with video of the slides and animations. Most include full-text papers. Interactive, searchable transcripts and closed captioning are now available for most presentations.
Search our growing collection of more than 18,000 conference presentations, including many plenaries and keynotes.